NASDAQ$TCMD

Tactile Systems Technology Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Tactile Systems Technology, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2024, with significant increases in total revenue, gross margin, and net income.

Tactile Systems Technology, Inc. delivered a strong performance in Q4 2024, with total revenue increasing by 10% year-over-year to $85.6 million. The company also saw an increase in gross margin to 75% and net income to $9.7 million, demonstrating consistent profitability and operational efficiency.

  • Total revenue increased 10% year-over-year to $85.6 million in Q4 2024.
  • Gross margin improved to 75% in Q4 2024, up from 72% in Q4 2023.
  • Net income reached $9.7 million, an increase from $8.2 million in Q4 2023.
  • Adjusted EBITDA grew to $16.2 million in Q4 2024, compared to $15.4 million in Q4 2023.

Headline financials

Total Revenue

$85.6M

Previous: $77.7M+10.2%
EPS (adj)

$0.40

Previous: $0.37+8.1%
Gross margin

75.0%

Previous: 72.0%+4.2%
Adjusted EBITDA

$16.2M

Previous: $15.4M+5.5%
Capital Expenditures

-$492K

Previous: -$940K+47.7%
Net Income

$9.72M

Previous: $8.2M+18.5%
Operating Income

$12.5M

Previous: $11.8M+6.1%
Gross Profit

$64.4M

Previous: $56M+14.9%
R&D Expense

$2.04M

No prior period

Revenue & EPS history

Tactile Systems · Revenue · Quarterly

$85.6M

Q4 2024+10.2%vs Q4 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Tactile Systems · $68.3M total across 2 segments · Q2 2023

  • Lymphedema products
    $60M+16.2%
  • Airway clearance products
    $8.34M+4.1%

Forward guidance

For the full year 2025, Tactile Systems Technology, Inc. expects total revenue to be in the range of $316 million to $322 million, representing an 8% to 10% year-over-year growth. Adjusted EBITDA is projected to be between $35 million and $37 million.

Tailwinds

  • Expected total revenue growth of approximately 8% to 10% year-over-year in 2025.
  • Anticipated continued profitability with adjusted EBITDA guidance of $35 million to $37 million.
  • Confidence in advancing market leadership in 2025.
  • Commitment to investing in strategic priorities to enhance patient experience.
  • Focus on improving access to care, expanding treatment options, and supporting the end-to-end patient journey.

Headwinds

  • Adjusted EBITDA guidance for 2025 ($35 million to $37 million) is slightly lower than the actual adjusted EBITDA for 2024 ($37.1 million).
  • The guidance range for net income in 2025 ($15.75 million to $17.15 million) is lower than the net income reported for 2023 ($28.515 million).
  • Potential impacts of inflation, rising interest rates, or a recession could affect future results.
  • Risks related to obtaining reimbursement from third-party payers for products.
  • Possible challenges from intense competition and price increases for supplies and components.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+3.1%

Avg return

Earnings day

+3.6%

Avg return

5 days after

+5.9%

Avg return

30 days after

64%

29 / 45 earnings

Positive

+40.6%

Q3 2025

Best reaction

-29.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+7.2%+14.5%+12.2%
Q4 2025+17.4%+2.2%-7.0%
Q3 2025+40.6%+57.6%+70.0%
Q1 2025-29.0%-31.6%-27.5%
Q4 2024-13.3%-16.6%-25.6%
Q3 2024-8.6%+2.2%+29.5%
Q2 2024+7.2%+8.6%+8.4%
Q1 2024+1.1%-2.6%-15.2%
Q4 2023-5.4%+8.0%+12.6%
Q3 2023-22.8%-16.9%+1.3%
Q2 2023-14.7%-10.2%-10.1%
Q1 2023+14.0%+15.7%+29.6%
Q4 2022+2.4%+7.6%+13.5%
Q3 2022+17.8%+27.5%+49.9%
Q2 2022+18.2%+15.0%+6.5%
Q1 2022+2.4%-22.9%-41.8%
Q4 2021+7.3%+29.9%+30.6%
Q3 2021-22.9%-22.1%-44.1%
Q2 2021-9.1%-10.8%-8.6%
Q1 2021-7.5%-2.4%-9.0%
Q4 2020-10.4%-15.0%-13.7%
Q3 2020+5.4%-2.7%+14.4%
Q2 2020-13.3%-8.4%-9.9%
Q1 2020-1.0%+3.2%+4.8%
Q4 2019-2.8%-6.3%-28.2%
Q3 2019+7.8%+12.4%+35.8%
Q2 2019-9.6%-7.6%-11.3%
Q1 2019+4.5%+4.0%-4.6%
Q4 2018+0.4%+2.9%-27.5%
Q3 2018-7.9%-5.6%-18.2%
Q2 2018+13.4%+12.4%+37.6%
Q1 2018+20.0%+26.8%+41.2%
Q4 2017+7.8%+1.6%-0.8%
Q3 2017-10.4%-7.6%-1.1%
Q2 2017+17.4%+7.7%+19.3%
Q1 2016+13.9%+22.1%+31.1%
Q1 2017+13.9%+22.1%+31.1%
Q1 2015+17.7%+10.2%+6.1%
Q4 2016+17.7%+10.2%+6.1%
Q4 2014+17.7%+10.2%+6.1%
Q3 2015+7.6%+2.1%-11.1%
Q3 2016+7.6%+2.1%-11.1%
Q4 2015+6.8%+3.9%+31.8%
Q2 2016+6.8%+3.9%+31.8%
Q2 2015+6.8%+3.9%+31.8%
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro